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Abstract
Background—Although c-kitpos cardiac stem cells (CSCs) preserve left ventricular (LV) 
function and structure after myocardial infarction (MI), CSC doses have been chosen arbitrarily 
and the dose-effect relationship is unknown.
Methods and Results—Rats underwent a 90-min coronary occlusion followed by 35 days of 
reperfusion. Vehicle or CSCs at 5 escalating doses (0.3 ×106, 0.75 ×106, 1.5 ×106, 3.0 ×106, and 
6.0 ×106 cells/heart) were given intracoronarily 4 h after reperfusion. The lowest dose (0.3 ×106) 
had no effect on LV function and morphology, whereas 0.75, 1.5, and 3.0 ×106 significantly 
improved regional and global LV function (echocardiography and hemodynamic studies). These 
three doses had similar effects on echocardiographic parameters (infarct wall thickening fraction, 
LV end-systolic and end-diastolic volumes, LV ejection fraction) and hemodynamic variables (LV 
end-diastolic pressure, LV dP/dtmax, preload adjusted maximal power, end-systolic elastance, 
preload recruitable stroke work), and produced similar reductions in apoptosis, scar size, infarct 
wall thinning, and LV expansion index and similar increases in viable myocardium in the risk 
region (morphometry). Infusion of 6.0 ×106 CSCs markedly increased post-procedural mortality. 
GFP and BrdU staining indicated that persistence of donor cells and formation of new myocytes 
were negligible with all doses.
Conclusions—Surprisingly, in this rat model of acute MI, the dose-response relationship for 
intracoronary CSCs is flat. A minimal dose between 0.3 and 0.75 ×106 is necessary for efficacy; 
above this threshold, a four-fold increase in cell number does not produce greater improvement in 
LV function or structure. Further increases in cell dose are harmful.
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Over the past decade, several types of stem/progenitor cells have undergone intensive 
investigation in preclinical models and clinical trials. Among the various cells tested, c-
kitpos cardiac stem cells (CSCs), characterized by the expression of the surface receptor 
tyrosine kinase c-kit, appear particularly promising.1 Several groups have reported that 
administration of CSCs improves LV function and structure after myocardial infarction (MI) 
in a variety of animal models.2–7 Using autologous or syngeneic c-kitpos CSCs, we have 
previously shown that transplantation of these cells attenuates LV dysfunction and 
remodeling in the settings of both acute and chronic MI in rodents1, 4, 8–11 and pigs.12 
Encouraging results were obtained in SCIPIO (Stem Cell Infusion in Patients with Ischemic 
Cardiomyopathy; NCT00474461), a phase I, open-label, randomized study designed to 
investigate the safety and feasibility of autologous CSC infusion in patients with severe 
heart failure resulting from ischemic cardiomyopathy.13, 14 The potential therapeutic utility 
of c-kitpos CSCs is further supported by the fact that these cells can be isolated from small 
fragments of cardiac tissue and expanded for subsequent autologous administration.1, 15, 16
However, despite these encouraging results, many questions pertaining to the therapeutic 
efficacy of CSCs remain unanswered. One of the most important is the dose of CSCs, which 
so far has been chosen rather arbitrarily; specifically, what is the dose-response relationship 
for CSC therapy? In our previous studies, we found that intracoronary administration of 
1×106 CSCs produced beneficial effects on LV function and structure in rats after acute9, 11 
and chronic MI.8 However, the optimal cell dosage for this approach, and whether higher 
doses would result in greater benefit, remain unknown; as mentioned above, the 1×106 dose 
was chosen arbitrarily. In the current study, we used the same model as in our previous 
investigation9 (intracoronary administration of CSCs in rats with acute MI) and infused 
escalating cell doses to delineate the dose-dependency of the effects of CSCs on cardiac 
repair. Surprisingly, we found that increasing the dose of CSCs above the therapeutic 
threshold does not result in greater benefit.
Methods
All animal experiments were performed in accordance with the Guide for the Care and Use 
of Laboratory Animals published by the U.S. National Institutes of Health (Eighth Edition, 
Revised 2010) and with the guidelines of the Animal Care and Use Committee of the 
University of Louisville, School of Medicine (Louisville, KY, USA).
Isolation and expansion of c-kitpos CSCs
c-kitpos CSCs were prepared using a modification of the method described by Beltrami et 
al.1 Briefly, cardiac cells were isolated from adult male Fischer 344 rats (4–6 months of 
age), the non-myocyte population was separated from myocytes by gravity sedimentation, 
counted (number of cells determined), and centrifuged at 600 g for 10 min at RT. Small 
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intact cells were resuspended and the cells seeded onto two 150 mm dishes in F12K medium 
with 5% FBS (HyClone), 10 ng/ml bFGF (Peprotech), and 10 ng/ml LIF (Chemicon) (RCSC 
medium). After six days of expansion, c-kitpos cells were sorted with magnetic beads using a 
rabbit c-kit antibody (H-300, Santa Cruz). c-kitpos cells were collected with magnetic beads 
(Dynal) coated with anti-rabbit IgG and maintained in culture with RCSC medium. The 
recovery of c-kitpos CSCs was determined by flow cytometry staining with an r-
phycoerythrin-conjugated rat monoclonal anti-c-kit antibody (Pharmingen). CSCs were 
labeled with GFP by lentiviral transduction. GFPpos CSCs were selected by blasticidin 
resistance. c-kitpos CSCs from passages 4–6 were used in all in vivo studies of post-MI CSC 
transplantation. The purity of sorted cells was determined by FACS.
Experimental MI and cell injection
Induction of MI and intracoronary injection of labeled cells in rats were have been 
previously.9, 11 Briefly, Female Fischer 344 rats (age 10–12 weeks; weight 174 ± 8 g) were 
anesthetized with ketamine (37 mg/kg) and xylazine (5 mg/kg) and mechanically ventilated. 
Anesthesia was maintained with isoflurane (1–3%). All animals underwent a 90-min 
occlusion of the left anterior descending coronary artery followed by reperfusion (Figure 1), 
and the chest was closed. Four hours after reperfusion, rats were reanesthetized, the chest 
reopened, and a thin catheter (Intracath, 22G, Becton Dickinson) was advanced into the 
aortic root via the left ventricular (LV) apex.8, 9, 11 Washed CSCs at doses of 0 (vehicle), 
0.3, 0.75, 1.5, 3.0, or 6.0 million (×106) were suspended in 1 ml PBS and injected into the 
aortic root (Figure 1).8, 9, 11 Rats were followed up for 35 days after cell application and 
then euthanized for histological studies. For tracking proliferating cells, rats were fed 5-
bromo-2’-deoxyuridine (BrdU) in drinking water during the 35-day follow-up (Figure 1).
Transthoracic echocardiography and hemodynamic measurements
Echocardiography was performed under light anesthesia (pentobarbital, 25 mg/kg, i.p.) as 
described previously8, 9, 17using an HDI 5000 echocardiography machine (Philips Medical 
Systems, Besl, The Netherlands) equipped with 15-7 MHz linear broadband and 12-5 MHz 
phased array transducers. Serial echocardiograms were obtained at baseline (BSL, 2 days 
before coronary occlusion) and at 48 h and 35 days after treatment. Short-axis 2D and M 
mode images were recorded.8, 9, 17 Systolic and diastolic anatomic parameters were obtained 
from M-mode tracings at the midpapillary level. LV volume was calculated by Teichholz 
formula and the ejection fraction (EF) was calculated by M-mode quantification formula. 
LV area was measured from short-axis 2D images. All measurements were averaged in three 
consecutive cardiac cycles and analyzed off-line by a single blinded observer using the 
COMPACS image analysis software. Hemodynamic measurements were performed at the 
35-day follow-up, just before euthanasia, using a 2.0 F Millar’s Mikro-Tip® ultra-miniature 
PV loop catheters (SPR-869; Millar Instruments, Houston, TX) as described.8, 11 In brief, 
rats were anesthetized with ketamine (37 mg/kg) and xylazine (5 mg/kg), intubated, and 
mechanically ventilated. Anesthesia was maintained with 1% isoflurane and the core 
temperature kept at 37.0°C with a heating pad throughout the study. A 2F PV loop catheter 
catheter (SPR-869, Millar Instruments) was inserted into the right carotid artery and 
advanced into the LV cavity. The right jugular vein was cannulated for fluid administration. 
After 20 min of stabilization, the PV signals were recorded continuously with an ARIA PV 
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conductance system (Millar Instruments) coupled with a Powerlab/4SP A/D converter (AD 
Instruments), stored, and displayed on a personal computer. PV relations were assessed by 
transiently compressing the inferior vena cava with a cotton swab. Parallel conductance 
from surrounding structures was calculated by injecting a small bolus of 30% NaCl through 
the jugular venous cannula. LV end-diastolic pressure (LVEDP), dP/dt, preload adjusted 
maximal power (PAMP), end-systolic elastance (Ees), and preload recruitable stroke work 
(PRSW) were calculated using the PVAN software program (Millar).
Morphometry and histology
After the hemodynamic measurements, a polyethylene catheter filled with phosphate buffer 
(0.2 M, pH 7.4) and heparin (100 IU/ml) was advanced to the ascending aorta via the right 
carotid artery. In rapid succession, the heart was arrested in diastole by injecting 1.0 ml of a 
mixture of cadmium chloride (100 mM)/potassium chloride (3 M) through the jugular 
venous cannula. The heart was then excised and perfused retrogradely with phosphate buffer 
for ~3 min to flush out residual blood in the coronary circulation, followed by perfusion 
with 10% neutral buffered formalin solution for 15 min. Perfusion pressure was maintained 
between 60 and 80 mmHg while end-diastolic pressure was kept at 8 mmHg. After 
perfusion-fixation, the atria and right ventricle were dissected from the left ventricle. The 
LV weight, volume, and the longitudinal intracavitary axis (LV cavity length) were 
measured to evaluate LV gross morphology.8, 11 The heart was cut into four transverse 
slices (~ 2-mm thick), which were processed, embedded in paraffin, sectioned at 4-µm 
intervals, and stained with Masson’s trichrome, picrosirius red, or antibodies against specific 
cell markers. Images were acquired digitally and analyzed using NIH ImageJ (1.44p). From 
the Masson’s trichrome-stained images, morphometric parameters including risk area, 
infarct size, and viable myocardium in the risk were measured in each section.8, 11 To 
evaluate cardiac fibrosis, LV sections were stained with picrosirius red and collagen content 
was quantitated in images taken under polarized light.8, 11
Immunohistochemistry
Immunofluorescence staining was performed in formalin-fixed, 4-µm-thick histological 
sections and analyzed by confocal microscopy for GFP, BrdU, α-sarcomeric actin (α-SA), 
TUNEL positive nuclei, and isolectin. Engraftment and proliferation in LV cross-sections 
were assessed by staining with antibodies against GFP or BrdU, respectively, which were 
then counterstained with α-SA. Capillary density was determined in sections stained with 
FITC-conjugated isolectin. Apoptotic cells were identified by TUNEL staining. Images were 
acquired and cells staining positive for each of these markers counted and normalized per 
mm2.
Statistical analysis
All data are expressed as means ± SEM. Echocardiographic data were performed by two-
way repeated-measures ANOVA followed by Student’s t-tests with Bonferroni correction 
for intra- and inter-group comparisons. All parametric data including morphometric, 
histologic, immunohistochemical, and hemodynamic data were analyzed by one-way 
ANOVA followed by the Student’s t-tests with Bonferroni correction for inter-group 
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comparisons. Mortality was analyzed by the χ2 test. All analyses were conducted with 
SigmaStat3.5. Values of P<0.05 were considered significant.
Results
Exclusions and gross measurements
Of the 82 rats enrolled into this study, 32 died during the course of the experiment (Table). 
One (in the 0.75×106 group) of the 32 rats died of ventricular fibrillation during coronary 
occlusion and the remaining 31 within 48 h after the intracoronary infusion. The mortality 
rate was similar among the groups (28.6% with vehicle, 30.0% with 0.3 ×106, 26.7% with 
0.75 ×106, 30.8% with 1.5 ×106, and 33.3% with 3.0 ×106) except for the 6.0 ×106 group, in 
which mortality was 80% (12 out of 15), significantly higher (P<0.05) than in the other five 
groups (Table). Thus, a total of 50 rats (10 in the vehicle, 7 in the 0.3 ×106, 11 in the 0.75 
×106, 9 in the 1.5 ×106, 10 in the 3.0 ×106, and 3 in the 6.0 ×106 group) completed the 
protocol. Because only three rats survived in the 6.0 ×106 group, and because of the obvious 
toxicity of this CSC dose, these animals were not included in the analysis of cardiac function 
and structure.
LV weight and LV/body weight ratio were lower in rats treated with CSCs at doses of 0.75 
×106 or higher compared with the vehicle group. Postmortem gross measurements 
conducted in the diastolically arrested, perfusion-fixed heart revealed a shorter LV 
longitudinal axis and a smaller chamber volume in rats receiving 0.75–3.0 ×106 CSCs 
compared with rats receiving vehicle (Figure 2).
Myocardial engraftment of transplanted CSCs
Myocardial engraftment of the transplanted CSCs (or their progeny) was determined by 
counting the number of GFPpos cells on LV sections after immunofluorescence staining for 
GFP (Figure 3A). As expected, no GFP signal was detected in the 10 hearts in the vehicle-
treated group. GFPpos cells in the 0.75, 1.5, and 3.0 ×106 groups were found in 9/11, 8/9, 
and 9/10 hearts, respectively, in the risk region, and in 5/11, 6/9, and 5/10 hearts, 
respectively, in the remote region. Quantitative analysis of the hearts with detectable GFP 
signals revealed that the number of GFPpos cells increased dose-dependently with the 
escalating doses both in the risk and remote (noninfarcted) regions (Figure 3B). At any 
given dose, the number of GFPpos cells was greater in the risk region vs. the remote region; 
however, in both cases, the absolute number of GFPpos cells was extremely low (<50 cells/
10,000 nuclei in the risk region and <20 cells/10,000 nuclei in the remote region) (Figure 
3B). Thus, intracoronary infusion of CSCs resulted in a dose-dependent increase in 
myocardial engraftment at 35 days after transplantation of CSCs, but the number of 
engrafted cells was minuscule, too low to account for functional or structural benefits.
LV morphometric analysis
Morphometric analysis indicated that neither infarct size nor viable myocardium was altered 
in the 0.3 ×106 group compared with vehicle (Figure 4). Despite similar risk regions among 
groups, CSCs at doses of 0.75 ×106 and higher significantly reduced infarct size (54.4±2.1% 
of the risk region in the vehicle group vs. 45.1±2.0% in the 0.75 ×106, 44.2±2.3% in the 1.5 
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×106, and 43.8±3.7% in the 3.0 ×106, P <0.05 for all comparisons), increased infarcted wall 
thickness (1.44±0.07 mm in the vehicle group vs. 2.03±0.12 in the 0.75 ×106 [P<0.01], 
1.98±0.16 in the 1.5 ×106 [P<0.05], and 2.21±0.14 in the 3.0 ×106 [P<0.01]), increased the 
amount of viable tissue within the risk region (45.6±2.1% in the vehicle group vs. 
54.9±2.0% in the 0.75 ×106. 55.8±2.3% in the 1.5 ×106, and 56.2±3.7% in the 3.0 ×106, P 
<0.05 for all comparisons), and limited LV dilation, as indicated by the LV expansion index 
(0.83±0.04 in the vehicle group vs. 0.56±0.04 in the 0.75 ×106, 0.58±0.05 in the 1.5 ×106, 
and 0.54±0.05 in the 3.0 ×106, P<0.01 for all comparisons) (Figure 4). Thus, in terms of 
morphometric variables, the threshold for CSC efficacy lies between the 0.3 and 0.75 ×106 
doses; above this threshold, there was no indication of a dose-dependent effect of CSCs as 
the dose increased from 0.75 to 3.0 ×106 (Figure 4).
Collagen content in the risk region was reduced by CSC administration at a dose of 0.75 
×106 or higher (P<0.05 vs. vehicle for all groups), but not at the dose of 0.3 ×106; again, the 
reduction did not exhibit a dose-dependent pattern (Figure 5). None of the CSC doses had 
any effect on collagen in the remote region (Supplemental Figure 1).
Echocardiographic and hemodynamic analyses
At baseline (before MI), all parameters of LV function, measured by echocardiography, 
were similar among groups (Figure 5). At 48 h after MI, the degree of LV dysfunction did 
not differ among the groups, indicating that the extent of injury sustained during MI was 
comparable. As expected, in vehicle-treated rats the infarct wall thickness in systole (IWTs), 
infarct wall thickening fraction (IW ThF), fractional shortening (FS), and ejection fraction 
(EF) decreased while LV end-systolic diameter (LVESD), LV end-systolic area (LVAs), and 
LV end-systolic (LVESV) and end-diastolic volume (LVEDV) increased at the 35-day 
follow-up compared with baseline (Figure 5). In rats that received 0.3 ×106 CSCs, none of 
these parameters was different from the vehicle group, indicating that this dose is not 
effective. In contrast, in rats that received a dose of 0.75 ×106 CSCs or greater, these 
parameters were improved, so that the IW ThF, FS, EF, and FAC were greater and the 
LVESD, LVAs, LVESV and LVEDV smaller compared with vehicle-treated rats (Figure 
5B). However, in the groups receiving 0.75, 1.5, and 3.0 ×106, there was no discernible 
dose-dependent pattern with respect to any of these echocardiographic variables at the 35-
day follow-up (Figure 5B).
Taken together, the echocardiographic data indicate that CSCs improved LV function when 
the dose exceeded a threshold between 0.3 and 0.75 ×106; increasing the cell dose above 
0.75 ×106 did not produce greater effects.
Consistent with the echocardiographic data, hemodynamic studies (performed before 
euthanasia using the conductance [Millar] catheter) showed that the lowest dose of CSCs 
(0.3 ×106) did not alter hemodynamic variables compared with the vehicle-treated group 
(Figure 6). However, CSCs at doses of 0.75 ×106 and greater produced significant 
improvements in LVEDP, dP/dtmax, dP/dtmax/EDV, preload adjusted maximal power 
(PAMP), end-systolic elastance (Ees), and preload recruitable stroke work (PRSW) (Figure 
6). As was the case for the echocardiographic data, there was no appreciable difference 
between doses of 0.75, 1.5 and 3.0 ×106.
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The number of TUNEL positive cells was counted in approximately 0.5% of total nuclei in 
both the risk and remote regions (Figure 7). The 0.75 ×106 dose produced a dramatic 
reduction in apoptotic cells in both regions compared with vehicle; the effects of the 1.5 
×106 and 3.0 ×106 doses were similar (Figure 7).
Cellular proliferation
BrdU incorporation was analyzed in the vehicle, 0.75 ×106, 1.5 ×106, and 3.0 ×106 groups, 
in which rats received BrdU in the drinking water during the 35-day follow-up. The total 
number of BrdU positive (BrdUpos) cells was higher in the 3.0 ×106 group than in vehicle-
treated hearts, both in the risk region and in the remote region (Figure 8B, upper panel). 
Although the total number of BrdUpos cells was higher in the 0.75 and 1.5 ×106 groups than 
in the vehicle group, the differences were not statistically significant.
Co-staining of tissue with BrdU and α-sarcomeric actin (α-sarc) antibodies showed no 
BrdUpos/α-sarcpos cells in the vehicle-treated hearts (Figure 8B, middle panel). A dose-
dependent increase was noted in the three CSC-treated groups, both in the risk and remote 
regions (Figure 8B middle panel). There were no significant differences among groups in 
the either the risk or the remote region. Further analyses after co-staining with GFP revealed 
that a minority of the BrdUpos/α-sarcpos cells expressed GFP, indicating that they were the 
transplanted cells or their progeny (Figure 8B, lower panel).
Taken together, the BrdU data indicate that administration of escalating doses of CSCs was 
associated with a dose-dependent increase in the numbers of BrdUpos and BrdUpos/α-sarcpos 
cells, suggesting that CSC treatment dose-dependently promoted myocyte proliferation. A 
minority of newly-formed myocytes were derived from the transplanted CSCs. However, 
since the absolute numbers of BrdUpos/α-sarcpos cells were extremely low (<10/10,000 
nuclei), it is unlikely that this increase in myocyte proliferation contributed importantly to 
the beneficial effects of CSCs.
Capillary density
Isolectin-stained capillaries averaged approximately 800/mm2 both in the risk and remote 
regions of the vehicle-treated hearts (Supplemental Figure 2). Three escalating doses of 
CSCs (0.75, 1.5, and 3.0 ×106) dose-dependently increased capillary density in both the risk 
and remote regions; compared with vehicle-treated hearts, the density was significantly 
higher in the 1.5 ×106 and 3.0 ×106 groups in the risk region, and in the 3.0 ×106 group in 
the remote region (Supplemental Figure 2).
Discussion
The present study was undertaken to determine whether the effects of CSC therapy follow a 
dose-dependent pattern. The salient results can be summarized as follows. In rats 
undergoing intracoronary infusion of syngeneic CSCs after acute MI, i) 0.3 ×106 CSCs did 
not produce any beneficial effect on LV structure or function 35 days later; ii) escalating 
doses of CSCs (0.75 ×106. 1.5 ×106, and 3.0 ×106) resulted in a dose-dependent increase in 
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the myocardial engraftment of the transplanted cells at 35 days, but the absolute number of 
these cells was so low (<50 cells/10,000 nuclei) that it was unlikely to contribute 
significantly to the beneficial effects of CSC therapy; iii) 6.0 ×106 CSCs resulted in 
significantly higher mortality, possibly due to extensive microembolization; iv) doses of 
0.75, 1.5. and 3.0 ×106 resulted in improved LV structure, as manifested by a shortened LV 
longitudinal axis, decreased chamber volume, reduced scar size, thicker infarcted LV wall, 
restrained LV dilation, reduced fibrosis, and increased content of viable myocardium in the 
risk region; v) this improvement in LV structure was associated with improved regional and 
global LV function, as demonstrated by two independent techniques: echocardiography 
(increased IW ThF, reduced LVESV, and increased LVEF) and hemodynamic studies 
(lowered LVEDP enhanced dP/dtmax, and increased PAMP, Ees, and dP/dtmax/EDV); vi) 
neither the improvement in structure nor the improvement in function associated with 0.75 
×106, 1.5 ×106, and 3.0 ×106 CSCs showed a dose-dependent pattern; vii) all three doses of 
CSCs reduced apoptosis to a similar extent in both the infarcted and the noninfarcted 
myocardium; and viii) these three doses produced a dose-dependent increase in the 
formation of new myocytes and capillaries, but the number of new myocytes was 
exceedingly low. Taken together, these results lead to the conclusion that, in the rat, the 
benefits of intracoronary infusion of CSCs after acute MI are not dose-dependent. Although 
many previous studies have examined the effects of CSCs in rodents,1, 2, 8, 9, 11, 18–23 to our 
knowledge this is the first analysis of the dose-dependence of these effects.
The reason for using the rat MI model and this range of CSC doses was that our previous 
studies demonstrated that intracoronary administration of 1 ×106 CSCs produced beneficial 
effects on LV function and morphology in this same rat model.8, 9, 11 We used intracoronary 
infusion of CSCs, rather than intramyocardial injection, for several reasons. Clinically, the 
technique for intracoronary delivery is similar to that used for coronary angioplasty and 
allows rapid translation because many interventional cardiologists are well versed with this 
method.24 In addition, it is the most popular mode of cell delivery in the clinical setting, 
especially after acute MI, because it can be done simultaneously during a percutaneous 
coronary intervention for treating stenotic coronary arteries.25 It also enables stem cells to be 
selectively infused into the target area. Finally, intracoronary administration allows the cells 
to home to and engraft within the areas bordering the infarct zone in a broader, more 
homogeneous manner.
We found that the lowest dose of CSCs (0.3 ×106) was ineffective whereas the three higher 
doses of 0.75, 1.5, and 3.0 ×106 exerted clear beneficial effects on LV function (Figures 5 
and 6) and structure (Figures 2, 4, and 5) which, however, were not related to the dose. 
Thus, the threshold for efficacy in this model is between 0.3 and 0.75 ×106; above this 
threshold, the benefits do not increase as the dose of CSCs increases four-fold (from 0.75 to 
3.0 ×106). Our echocardiographic results were corroborated by the hemodynamic studies, 
which provide an assessment of function that is completely independent of 
echocardiography and that, unlike the echocardiographic data, is based on load-independent 
variables, i.e., dP/dtmax/EDV, PAMP, Ees, and PRSW.
In contrast to the functional data, myocyte and CSC proliferation and capillary density 
exhibited a dose-related pattern with doses of 0.75, 1.5, and 3.0 ×106 (Figure 8 and 
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Supplemental Figure 2). However, the increase in dose did not produce a proportionate 
increase in myocyte and CSC proliferation. Furthermore, the absolute cell numbers were 
extremely small and unlikely to have functional significance: for example, the number of 
BrdUpos/α-sarcpos cells was <10/10,000 nuclei, and the number of BrdUpos/α-sarcpos/
GFPpos cells was <4/10,000 nuclei (Figure 8 and Supplemental Figure 2).
The effects of the highest dose of CSCs (6.0 ×106) were not analyzed for two main reasons: 
first, the group size was too small (n=3) for meaningful statistical analysis, and second, the 
mortality in the this group was much higher than in the other four groups (80% vs. 27–33%, 
P<0.05 for all groups), making it possible that only the “healthiest” animals (those with 
either less cardiac injury or better overall conditions) may have survived the CSC infusion, 
thereby skewing the outcome in a manner that is unrelated to CSCs. Clearly, the maximal 
dose of CSCs that should be considered for experimental studies is the highest dose that 
does not cause safety concerns.
Most previous investigators studying the effects of different doses of cells with a 
regenerative capacity have found a positive dose-efficacy relationship. For instance, 
intramyocardial injection of escalating doses of human bone marrow-derived CD34pos cells 
in rats,26 human undifferentiated mesenchymal stem cells (MSCs) and differentiated 
cardiomyocyte-like cells (CLCs) in rats,27 and human cardiospheres in mice28 has been 
reported to impart dose-dependent functional and histological benefits. Intravenous delivery 
of MSCs in a porcine model of MI has also been reported to produce a dose-dependent 
beneficial effect on cardiac function.29 The reason for the apparent discrepancy between our 
study and these previous studies26–29is unclear, but may relate to the cell type (CSCs vs. 
bone marrow CD34pos cells, cardiospheres, MSCs, and CLCs), animal model (rats with 
reperfused MI vs. mice and pigs with permanent LAD ligation), and other methodological 
differences. A recent study by Dawkins et al30 in a porcine model of chronic MI found that 
intracoronary infusion of cardiosphere-derived cells (CDCs) at escalating doses of 6.25, 
12.5, and 25.0 ×106 led to equally enhanced preservation of LV function and tissue 
remodeling without manifestation of a dose-efficacy relationship. That study resembles ours 
in the sense that in both cases, no dose dependency was found over a four-fold range of cell 
numbers (0.75–3.0 ×106 in our study, 6.25–25 ×106 in that study).
One can only speculate as to why a four-fold increase in cell delivery (from 0.75 to 3.0 
×106) did not result in greater efficacy. We found that, regardless of the dose, the 
engraftment of CSCs was extremely low, implying that differentiation of transplanted cells 
into myocytes did not contribute importantly to the functional and structural effects of CSC 
therapy. We have previously found that CSCs act mainly via paracrine mechanisms,8, 11and 
it is unclear whether such mechanisms are dose-dependent. If the signals released by CSCs 
(cytokines, miRs, etc.) are amplified non-linearly by endogenous processes (i.e., if they act 
as triggers of endogenous repair mechanisms, such as mobilization of resident cardiac stem/
progenitor cells), then it is conceivable that increased doses of CSCs may not produce a 
greater response because the mobilization of repair mechanisms may be unrelated to the 
magnitude of the stimulus.
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In conclusion, this study demonstrates that intracoronary administration of syngeneic CSCs 
in rats with acute MI results in an improvement in LV function and structure, but the 
magnitude of this improvement is not dose-dependent. The threshold for efficacy is between 
0.3 and 0.75 ×106; above this threshold, the beneficial effects of CSCs on LV function and 
remodeling do not increase over a four-fold range (from 0.75 to 3.0 ×106). Higher doses 
have obvious toxic effects, as demonstrated by the increased mortality associated with the 
6.0 ×106 dose. Therefore, for practical purposes, the dose-efficacy relationship for 
intracoronarily administered CSCs in this model is flat. We also found that the engraftment 
of CSCs is negligible regardless of the dose used; even with the highest safe dose (3.0 ×106), 
engraftment was insufficient to account for the benefits afforded by CSC infusion. These 
results have obvious implications for the design of studies in rats. If these findings can be 
extrapolated to humans, they would suggest that increasing the dose of CSCs above a level 
found to be effective and safe may not lead to increased benefit and could potentially be 
harmful. Given that increasing the number of cells has inherent limitations in potentiating 
the beneficial effects of CSC therapy, the focus of our future endeavors should be on 
increasing the quality and potency of the limited number of cells that can be transferred as 
well as defining the best individual or combinatorial cell populations to maximize the 
beneficial outcome of cell-based interventional strategies.
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Figure 1. Experimental protocol
Fischer 344 female rats (age 3–4 months)
GFP-labeled syngeneic CSCs were injected into the aortic root during two 20-s occlusions 
of the ascending aorta and pulmonary artery, 10 min apart , and a 0.5 ml of volume was 
delivered each injection (CSCs were suspended in a total of 1.0 ml medium for each rat)
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Postmortem gross measurements were conducted in perfused hearts arrested in diastole. 
Data are means ± SEM.
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Figure 3. Myocardial engraftment of transplanted CSCs
(A). Representative images showing GFPpos cells in the border zone of the LV section from 
a rat that received 3.0 ×106 CSCs. (B). Quantitative analysis was performed in the hearts 
with detectable GFPpos cells. Data are means ± SEM.
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Figure 4. Morphometric analysis
(A). Representative Masson’s trichrome-stained LV sections from each of the six groups. 
Scar tissue and viable myocardium are identified in blue/white and red, respectively. (B). 
Quantitative analysis of LV morphometric parameters. The thickness of the infarcted wall 
was determined by averaging five measurements of LV wall thickness equally distributed 
within the infarcted LV region; risk region was defined as the LV area between the two 
edges of the infarct scar; and LV expansion index was calculated as (LV endocardial 
circumference/LV epicardial circumference) × (non-infarcted region wall thickness/risk 
region wall thickness). Data are means ± SEM.
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Figure 5. Echocardiographic assessment of LV function
(A) Representative M-mode images from the vehicle, 0.3 ×106, 0.75 ×106, 1.5 ×106, and 3.0 
×106, groups recorded at baseline (before MI), 48 h after MI, and 35 d after vehicle or CSC 
treatment. (B). Quantitative analyses of echocardiographic parameters at baseline (BSL), 48 
h after MI (48 h), and 35 d follow-up (35 d). IWTs, systolic infarcted wall thickness; 
LVESD, left ventricular end-systolic diameter; LVAs, left ventricular end-systolic area; FS, 
fractional shortening; EF, ejection fraction; FAC, fractional area change; IW ThF, infarcted 
wall thickening fraction; LVEDV, left ventricular end-diastolic volume; and LVESV, left 
ventricular end-systolic volume. Data are means ± SEM.
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Hemodynamic assessment of LV function at 35 d follow-up. LVEDP, left ventricular end-
diastolic pressure; PAMP, preload adjusted maximal power; Ees, end-systolic elastance; 
and PRSW, preload recruitable stroke work. Data are means ± SEM.
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Figure 7. Analysis of apoptosis by TUNEL staining
(A) Representative confocal microscopic images in the border zone of a 3.0 ×106 CSC-
treated rat showing TUNEL positive nuclei (green), DAPI staining (blue), and a merge of 
TUNEL and DAPI staining; (B) Quantitative analysis of TUNEL positive nuclei in the risk 
and remote (noninfarcted) region in the vehicle- and three doses of CSC-treated groups. 
Data are means ± SEM.
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Figure 8. Proliferation of transplanted CSCs
(A) Representative confocal microscopic images from a 3.0 ×106 CSC-treated rat showing 
BrdU uptake in the infarcted region during the 35 d follow-up. Yellow arrows indicate 
GFPpos cells that are BrdU positive. (B) Quantitative analysis of BrdUpos cells, BrdUpos/α-
sarcpos cells (cells with colocalization of BrdU [FITC] and α-sarcomeric actin [TRITC]), 
and BrdUpos/α-sarcpos/GFPpos cells (cells with colocalization of BrdU [FITC], α-sarcomeric 
actin [TRITC], and GFP [TRITC]) in the risk and remote (noninfarcted) regions. Data are 
means ± SEM.
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Vehicle 14 4 10 28.6*
0.3 ×106 CSCs 10 3 7 30.0*
0.75 ×106 CSCs 15 4 11 26.7*
1.5 ×106 CSCs 13 4 9 30.8*
3.0 ×106 CSCs 15 5 10 33.3*
6.0 ×106 CSCs 15 12 3 80.0
Total 82 32 50 39.0
*
P<0.05 vs. 6.0 ×106 CSCs
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